角膜共聚焦显微镜作为神经退行性疾病辅助检查的范围综述
该范围综述纳入50项研究,评估角膜共聚焦显微镜(CCM)在神经退行性疾病(NDDs)中检测角膜神经纤维变化的证据。结果显示CNFL和CNFD在帕金森病、多发性硬化、脑血管意外、肌萎缩侧索硬化、慢性炎性脱髓鞘性多发性神经病和COVID-19后神经病中 consistently 降低,但CNBD结果不一致。最强证据支持CCM在帕金森病和多发性硬化中的作用,但方法学异质性限制了可比性,需要标准化方案。
要点
- CNFL和CNFD是跨NDDs最可靠的CCM指标,支持其作为神经退行性变的客观生物标志物。
- 最强证据支持CCM用于帕金森病和多发性硬化。
- 图像采集、分析软件和研究设计的方法学异质性限制了可比性。
核心结论
- CNFL和CNFD是跨神经退行性疾病最可靠的CCM衍生指标,支持其作为神经退行性变的客观生物标志物的潜力。
- 虽然发现支持CCM作为辅助诊断工具的潜力,但方法学异质性限制了可比性,需要标准化成像和分析方案以促进更广泛的临床应用和验证。
研究设计与样本
- 范围综述,遵循PRISMA-ScR指南,全面检索PubMed和Scopus,纳入报告定量CCM指标(包括CNFD、CNBD和CNFL)的横断面和纵向研究,对NDDs患者的研究进行叙述性综合。
- 共纳入50项研究:帕金森病(n=13)、多发性硬化(n=11)、脑血管意外(n=7)、COVID-19后神经病(n=5)、肌萎缩侧索硬化(n=4)、慢性炎性脱髓鞘性多发性神经病(n=4)、阿尔茨海默病(n=3)、Fabry病(n=2)和1型神经纤维瘤病(n=1)。
主要发现
- CNFL和CNFD在帕金森病、多发性硬化、脑血管意外、肌萎缩侧索硬化、慢性炎性脱髓鞘性多发性神经病和COVID-19后神经病中 consistently 降低。
- CNBD结果不一致。
- 最强证据支持CCM在帕金森病和多发性硬化中的作用。
临床怎么用
- CCM可作为神经退行性疾病的辅助诊断和监测工具,尤其对帕金森病和多发性硬化证据最强。
- 临床应用中应关注CNFL和CNFD这两个最可靠的CCM指标。
- 由于方法学异质性,目前结果的可比性有限,需等待标准化方案推广。
局限性
- 图像采集、分析软件和研究设计的方法学异质性限制了研究间的可比性。
- 需要标准化的成像和分析协议以实现更广泛的临床应用和跨NDDs验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Corneal confocal microscopy (CCM) is a non-invasive imaging technique that enables quantification of the corneal sub-basal nerve plexus and has emerged as a potential surrogate biomarker for peripheral neurodegeneration. This scoping review evaluated current evidence on the use of CCM in assessing corneal nerve fibre changes across neurodegenerative diseases (NDDs) and explored its potential as a paraclinical diagnostic and monitoring tool. A comprehensive search of PubMed and Scopus was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines to identify studies reporting quantitative CCM metrics, including corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fibre length (CNFL). Both cross-sectional and longitudinal studies of patients with NDDs were included, and findings were narratively synthesised. 50 studies were included: Parkinson's disease (n=13), multiple sclerosis (n=11), cerebrovascular accidents (n=7), post-COVID-19 neuropathy (n=5), amyotrophic lateral sclerosis (n=4), chronic inflammatory demyelinating polyneuropathy (n=4), Alzheimer's disease (n=3), Fabry disease (n=2) and neurofibromatosis type 1 (n=1). CNFL and CNFD were consistently reduced in Parkinson's disease, multiple sclerosis, cerebrovascular accidents, amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy and post-COVID-19 neuropathy, whereas CNBD results were inconsistent. The strongest evidence supported the role of CCM in Parkinson's disease and multiple sclerosis. CNFL and CNFD emerged as the most reliable CCM-derived metrics across NDDs, supporting their potential as objective biomarkers for neurodegeneration. While findings support the potential of CCM as a paraclinical diagnostic tool, methodological heterogeneity in image acquisition, analysis software and study design limited comparability. Standardised imaging and analysis protocols are needed to enable broader clinical application and validation across NDDs.
引用
- Oreskovic E, Petzold A, Petropoulos IN, et al. Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review. Br J Ophthalmol. 2026. PMID: 41605610. doi:10.1136/bjo-2025-328181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。